• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.巴西遗传性癌症风险综合征的遗传学:1682 例患者的综合分析。
Eur J Hum Genet. 2022 Jul;30(7):818-823. doi: 10.1038/s41431-022-01098-7. Epub 2022 May 9.
2
Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases.巴西遗传性乳腺癌/卵巢癌病例中种系致病性变异的谱。
Breast Cancer Res Treat. 2024 Oct;207(3):615-624. doi: 10.1007/s10549-024-07383-x. Epub 2024 Jun 14.
3
Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.土耳其特拉基亚地区高危 BRCA 相关乳腺癌/卵巢癌个体的遗传筛查结果。
J BUON. 2020 May-Jun;25(3):1337-1347.
4
Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.机会性检测 BRCA1、BRCA2 和错配修复基因可提高表型驱动遗传性癌症基因检测面板的检出率。
Int J Cancer. 2019 Nov 15;145(10):2682-2691. doi: 10.1002/ijc.32304. Epub 2019 Apr 15.
5
Genetic testing in Poland and Ukraine: should comprehensive germline testing of and be recommended for women with breast and ovarian cancer?波兰和乌克兰的基因检测:是否应推荐对乳腺癌和卵巢癌女性进行全面胚系检测?
Genet Res (Camb). 2020 Aug 10;102:e6. doi: 10.1017/S0016672320000075.
6
Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.BRCA1、BRCA2 和 TP53 致病性变异在巴西公共医疗服务的 HBOC 患者中的家族史和流行情况。
Sci Rep. 2022 Nov 3;12(1):18629. doi: 10.1038/s41598-022-23012-3.
7
Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.BRCA1/2 阴性的巴西患者中常见中等至高风险遗传性乳腺癌和卵巢癌易感基因种系变异。
Breast Cancer Res Treat. 2021 Feb;185(3):851-861. doi: 10.1007/s10549-020-05985-9. Epub 2020 Oct 30.
8
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.巴西非选择性卵巢癌患者中 BRCA1 和 BRCA2 致病性和可能致病性变异体的流行率。
BMC Cancer. 2019 Jan 3;19(1):4. doi: 10.1186/s12885-018-5235-3.
9
Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.巴西遗传性乳腺癌的种系分子数据:来自大型单中心分析的经验教训。
PLoS One. 2021 Feb 19;16(2):e0247363. doi: 10.1371/journal.pone.0247363. eCollection 2021.
10
Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.使用多基因panel 检测技术检测巴西乳腺癌患者的种系变异。
Sci Rep. 2022 Mar 9;12(1):4190. doi: 10.1038/s41598-022-07383-1.

引用本文的文献

1
Cancer genomics and bioinformatics in Latin American countries: applications, challenges, and perspectives.拉丁美洲国家的癌症基因组学与生物信息学:应用、挑战与前景
Front Oncol. 2025 Jul 9;15:1584178. doi: 10.3389/fonc.2025.1584178. eCollection 2025.
2
ACMG secondary findings in the Brazilian rare genomes project: insights from 5402 genome sequencing.巴西罕见基因组计划中的美国医学遗传学与基因组学学会次要发现:来自5402例基因组测序的见解
J Hum Genet. 2025 May 19. doi: 10.1038/s10038-025-01349-7.
3
Building a hereditary cancer program in Colombia: analysis of germline pathogenic and likely pathogenic variants spectrum in a high-risk cohort.在哥伦比亚建立遗传性癌症项目:高危队列中种系致病性和可能致病性变异谱分析
Eur J Hum Genet. 2025 Mar 10. doi: 10.1038/s41431-025-01807-y.
4
Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer?MUTYH致病变体的患病率与分布:它与乳腺癌风险增加有关吗?
Cancers (Basel). 2024 Jan 11;16(2):315. doi: 10.3390/cancers16020315.
5
Clinical genomics testing: mainstreaming and globalising.临床基因组学检测:主流化与全球化
Eur J Hum Genet. 2022 Jul;30(7):747-748. doi: 10.1038/s41431-022-01131-9.

巴西遗传性癌症风险综合征的遗传学:1682 例患者的综合分析。

The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients.

机构信息

Hospital Memorial Arcoverde, Arcoverde, Pernambuco, Brazil.

Universidade Luterana do Brasil, Programa de Pós-Graduação em Biologia Celular e Molecular Aplicada à Saúde, Canoas, Rio Grande do Sul, Brazil.

出版信息

Eur J Hum Genet. 2022 Jul;30(7):818-823. doi: 10.1038/s41431-022-01098-7. Epub 2022 May 9.

DOI:10.1038/s41431-022-01098-7
PMID:35534704
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9259741/
Abstract

Hereditary cancer risk syndromes are caused by germline variants, commonly in tumor suppressor genes. Most studies on hereditary cancer have been conducted in white populations. We report the largest study in Brazilian individuals with multiple ethnicities. We genotyped 1682 individuals from all country regions with Next-generation sequencing (NGS) panels. Most were women with a personal/family history of cancer, mostly breast and ovarian. We identified 321 pathogenic/likely pathogenic (P/LP) variants in 305 people (18.1%) distributed among 32 genes. Most were on BRCA1 and BRCA2 (129 patients, 26.2% and 14.3% of all P/LP, respectively), MUTYH (42 monoallelic patients, 13.1%), PALB2 (25, 7.8%), Lynch syndrome genes (17, 5.3%), and TP53 (17, 5.3%). Transheterozygosity prevalence in our sample was 0.89% (15/1682). BRCA1/BRCA2 double heterozygosity rate was 0.78% (1/129) for BRCA variants carriers and 0.06% (1/1682) overall. We evaluated the performance of the genetic testing criteria by NCCN and the Brazilian National Health Agency (ANS). The inclusion criteria currently used in Brazil fail to identify 17%-25% of carriers of P/LP variants in hereditary cancer genes. Our results add knowledge on the Brazilian spectrum of cancer risk germline variants, demonstrate that large multigene panels have high positivity rates, and indicate that Brazilian inclusion criteria for genetic testing should be improved.

摘要

遗传性癌症风险综合征是由种系变异引起的,通常发生在肿瘤抑制基因中。大多数遗传性癌症的研究都是在白种人群中进行的。我们报告了在具有多种族裔的巴西个体中进行的最大规模研究。我们使用下一代测序 (NGS) 面板对来自全国所有地区的 1682 个人进行了基因分型。大多数是有个人/家族癌症史的女性,主要是乳腺癌和卵巢癌。我们在 305 个人中发现了 321 个致病性/可能致病性 (P/LP) 变体,分布在 32 个基因中。大多数是 BRCA1 和 BRCA2(129 名患者,分别占所有 P/LP 的 26.2%和 14.3%)、MUTYH(42 名单等位基因患者,13.1%)、PALB2(25 名,7.8%)、Lynch 综合征基因(17 名,5.3%)和 TP53(17 名,5.3%)。我们样本中的 Transheterozygosity 患病率为 0.89%(15/1682)。BRCA1/BRCA2 双杂合率在 BRCA 变体携带者中为 0.78%(1/129),在所有患者中为 0.06%(1/1682)。我们评估了 NCCN 和巴西国家卫生署 (ANS) 的遗传检测标准的性能。巴西目前使用的纳入标准未能识别出 17%-25%的遗传性癌症基因 P/LP 变体携带者。我们的结果增加了对巴西癌症风险种系变体谱的了解,表明大型多基因面板具有较高的阳性率,并表明巴西的遗传检测纳入标准需要改进。